HER2 IHC is generally performed first in IBC to assess for HER2 protein expression and ISH is subsequently performed in cases with equivocal IHC results [score 2+: weak to moderate complete membrane staining in >10% of tumor cells, complete membrane staining that is intense but within ≤10% of tumor cells, or moderate to intense but incomplete membrane staining (basolateral or lateral)] [1] to further assess the HER2 gene amplification status. Here, ERBB2 is linked to neoplasm.